A hundred feet further
Release time:
2020-08-14
One Hundred Years Further
Group Company 2017 Outstanding Salesman Peak Pharmacy Xinhua Pharmacy Wang Xiuling
I have had 20 years since I entered Peak Pharmacy in 1997 . After being transferred to a large pharmacy in 2011 , he served as a store manager for seven consecutive years. He overfulfilled his task every year. He and the store were successively rated as "Outstanding Licensed Pharmacist Volunteer", "National Pharmacy Gold Medal Store Manager" and "National Pharmacy Top Ten Elite in Combined Drug Use" in Zhejiang Province. He was an advanced individual and advanced collective of pharmaceutical companies and group companies.
2017 , Xinhua Pharmacy, with the joint efforts of all employees, successfully completed the task targets issued by the company, with the annual completion rate reaching 123.75% . 2017 , we mainly did the following work:
to make stores with our own characteristics. After two years of exploration, Xinhua Pharmacy has cooperated with major foreign companies and has begun to break away from the traditional pharmacy model and gradually form the DTP pharmacy model. We have the most advanced Roche cold chain sales system, but also attracted more manufacturers are willing to cooperate with us, the new special drug products increased. We use the geographical advantage of Xinhua drugstore and cooperate with doctors to expand the sales and influence of Xinhua drugstore.
do sales at the same time do popularity, do popularity. In order to improve the popularity of pharmacies, we cooperate with various foundations to provide free drug donation services for patients in Jinliqu area, and there are special licensed pharmacists in charge of this work. At that time, in line with the mentality of not making money and earning popularity, I took over the service of giving medicine. Now there are more and more kinds of giving medicine and more and more foundations cooperating with us. However, each foundation also has particularly high requirements for stores, including online training, telephone training, teleconference, QQ training and so on every month. Although there are many trivial things, in addition to winning popularity, the sales and popularity of our stores are also increasing. In addition to Jinhua's local customers, there are also customers from surrounding counties and cities, Lishui, Quzhou, Jiangshan and other places. Our ultimate goal is that in Jinliqu area, no matter manufacturers, patients or doctors, when they need new special drug products, the first thing that comes to mind is Xinhua Pharmacy, a big pharmacy.
drug Osimertinib mesylate is a first-line anti-cancer drug taken by AstraZeneca lung cancer patients after drug resistance. The sales price is ,51,000 yuan per box. However, manufacturers have very strict control over sales areas and stores. There are only 6 in Zhejiang Province and only one in Jinliqu area. The size and address of stores, including the professionalism of licensed pharmacists serving patients, and the cooperation between stores and manufacturers are assessed. Due to the good foundation of cooperation in the early stage, the flowers finally fell to Xinhua drugstore. In 2017 , the sales volume excluding tax of this product alone reached 152 . The winning of the bid for this product means that Xinhua Pharmacy's influence in Jinliqu area has risen to another level.
is committed to serving the salesmen of major manufacturers and hospital doctors, and plays the role of intermediate bridge. If the salesman of the factory needs to purchase goods and check the flow direction, he will respond to any request. If the hospital doctor has any questions, I will also answer them. 2017 9 to 2018 1 , the provincial medical insurance and municipal medical insurance bureau issued many new medical insurance policies, including the price reduction of serious illness drugs and changes in the reimbursement process. I went to the municipal medical insurance bureau many times to communicate, got the latest news and reimbursement process, and called doctors and factory salesmen in major hospitals one by one, timely convey the medical insurance policy to patients so that more patients can benefit in time. There are designated pharmacies outside Jinhua city. under my service, many non-designated patients also buy drugs directly in our store.
pharmacies to achieve good performance, in addition to professional, quality service is the king, I always practice this, and continue to work hard. Because of this, the performance of Xinhua Pharmacy has also been booming in recent years, and I have also used this platform to get great promotion and countless honors. 2018 will usher in a more difficult year, but I am willing to go further. (According to Wang Xiuling's speech at the summary and commendation meeting of the group company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page